TScan Therapeutics, a Boston, MA-based company that designs therapies that reprogram a patient’s own T cells to fight cancer, raised its Series B financing, with over $48m secured since inception.
Backers included Bessemer Venture Partners, Google Ventures, founding investor Longwood Fund, Novartis Venture Fund, and Novartis Institutes of Biomedical Research (NIBR).
Led by David P. Southwell, Chief Executive Officer; Gavin MacBeath PhD, Chief Scientific Officer; Henry Rath, Chief Business Officer; and Robert Crane, Chief Financial Officer, TScan designs therapies that reprogram a patient’s own T cells to recognize and fight their cancer using naturally occurring TCRs that recognize shared cancer targets. The TScan discovery process is a proprietary genome-wide, high-throughput target identification screen, designed to rapidly identify the natural targets of TCRs.
The company is developing a portfolio of TCR therapies for patients suffering from both liquid and solid tumors.